Hypogonadism is a clinical syndrome resulting from failure of the gonads to produce physiological concentrations of sex hormones and/or normal gametes, due to pathology at the hypothalamic-pituitary-gonadal axis. [1-2] While typically a chronic condition, acute presentations occur in the context of pituitary apoplexy, testicular torsion, adrenal crisis from concurrent hypopituitarism, opioid-induced suppression, or anabolic steroid withdrawal. [1][3] The following is a clinically focused summary for emergency medicine and primary care evaluation.
1. History
- Onset and timeline: Sudden vs. gradual onset of symptoms; acute headache with visual changes suggests pituitary apoplexy [3-4]
- Sexual symptoms (highest specificity): Decreased libido, erectile dysfunction, loss of morning erections, decreased sexual activity [1-2]
- Nonspecific symptoms: Fatigue, low energy, depressed mood, poor concentration, reduced physical performance, sleep disturbance [1]
- Reproductive: Infertility, decreased ejaculate volume [1-2]
- Vasomotor: Hot flashes (particularly with abrupt testosterone withdrawal, e.g., post-orchiectomy or GnRH agonist use) [5]
- Important negatives: Anosmia (Kallmann syndrome), galactorrhea (prolactinoma), visual field deficits (sellar mass), headache severity and acuity [2]
2. Alarm Features
- Sudden severe headache + visual loss + ophthalmoplegia → pituitary apoplexy until proven otherwise [3-4][6]
- Hypotension, altered mental status, hyponatremia → concurrent adrenal crisis from ACTH deficiency [3][7]
- Bitemporal hemianopia or cranial nerve III/IV/VI palsy → sellar mass with chiasmal compression [6]
- Acute scrotal pain → testicular torsion (primary hypogonadism cause, surgical emergency)
- Meningismus → hemorrhagic pituitary apoplexy can mimic subarachnoid hemorrhage [4][8]
- Signs of panhypopituitarism: Hypothermia, bradycardia, hypoglycemia in addition to hypotension [7]
3. Medications
Causative medications (functional hypogonadism)
- Opioids: Most common drug-induced cause; prevalence of hypogonadism >50% in chronic users; μ-agonists (methadone, morphine) are most potent suppressors [5][9-10]
- Glucocorticoids: Prednisone ≥15 mg/day can suppress testosterone within 3 days [5]
- GnRH agonists/antagonists: Used in prostate cancer; cause castrate-level testosterone
- Anabolic-androgenic steroids: Withdrawal causes profound hypogonadotropic hypogonadism [1]
- Others: Ketoconazole, spironolactone, immune checkpoint inhibitors (hypophysitis), anticonvulsants, barbiturates [7][11]
Treatment medications (not typically initiated in ED)
- Testosterone replacement therapy (TRT) — various formulations [5][12]
- Clomiphene citrate (off-label for secondary hypogonadism with fertility preservation) [1]
Contraindicated medications in hypogonadal men
4. Diet
- No specific acute dietary triggers
- Obesity is a major contributor to functional hypogonadism; weight loss can increase endogenous testosterone [1][14]
- Fasting state is required for accurate testosterone measurement (testosterone drops postprandially) [2]
- Severe malnutrition and eating disorders suppress the HPG axis [5][7]
5. Review of Systems
- Neurologic: Headache, visual changes, diplopia, altered mental status (pituitary apoplexy) [3][6]
- Endocrine: Cold intolerance, weight changes, polyuria/polydipsia (concurrent pituitary deficiencies) [3]
- Musculoskeletal: Decreased muscle mass, bone pain, history of fragility fractures [5]
- Psychiatric: Depression, irritability, cognitive decline, poor concentration [1]
- Genitourinary: Erectile dysfunction, decreased libido, infertility, decreased testicular size, gynecomastia [5]
- Hematologic: Fatigue from anemia (common in hypogonadism) [2]
6. Collateral History and Family History
- Family history: Anosmia, delayed puberty, infertility, or midline defects in relatives suggest congenital hypogonadotropic hypogonadism (Kallmann syndrome — X-linked recessive ANOS1 mutation) [2]
- Substance use: Opioid use (prescription and illicit), anabolic steroid use, marijuana, alcohol [2][7]
- Collateral from partner: Confirm sexual dysfunction timeline, mood/behavioral changes
- Klinefelter syndrome: Family history of learning difficulties, tall stature, infertility [2]
- Hereditary hemochromatosis: Iron overload causing secondary hypogonadism [1]
7. Risk Factors
- Obesity (BMI >30): Most common cause of functional hypogonadism in middle-aged men [1]
- Chronic opioid use (>3 months): Prevalence of hypogonadism 50–85% [9-10]
- Type 2 diabetes / metabolic syndrome [2][15]
- Aging: Testosterone declines ~1–2% per year after age 30 [16]
- Pituitary adenoma (especially nonfunctioning macroadenoma) [3]
- Prior chemotherapy/radiation to testes or brain [1-2]
- Head trauma / TBI [1-2]
- HIV infection [1]
- Hemochromatosis [1]
- Chronic kidney disease, liver disease, COPD [17]
8. Differential Diagnosis
- Pituitary apoplexy — sudden headache, visual loss, hypotension; cannot-miss diagnosis [3-4]
- Testicular torsion — acute scrotal pain; surgical emergency
- Adrenal crisis — hypotension, hyponatremia, altered mental status; may coexist with hypogonadism in panhypopituitarism [7][11]
- Hypothyroidism — fatigue, cold intolerance, weight gain; overlapping symptoms [3]
- Depression — fatigue, low libido, poor concentration; significant symptom overlap [1]
- Opioid-induced endocrinopathy — hypogonadism + possible hypocortisolism [9-10]
- Prolactinoma — galactorrhea, visual field deficits, low testosterone with low/normal LH [5]
- Hemochromatosis — secondary hypogonadism with liver disease, skin bronzing, diabetes [1]
- Anabolic steroid withdrawal — profound hypogonadotropic hypogonadism with suppressed LH/FSH [1]
9. Past Medical History
- Prior testicular surgery, trauma, torsion, or cryptorchidism [1-2]
- History of mumps orchitis [2]
- Known pituitary adenoma or prior pituitary surgery/radiation [1-2]
- Chemotherapy or radiation therapy [1]
- Chronic opioid or glucocorticoid use [5][9]
- Diabetes, metabolic syndrome, obesity [2]
- Prior fragility fractures or known osteoporosis [5]
- Sleep apnea (both a risk factor and contraindication to TRT) [1]
- Thromboembolism history [18]
10. Physical Exam
- Vitals: Hypotension (adrenal crisis), bradycardia (hypothyroidism), fever (pituitary apoplexy)
- Eyes: Visual field testing by confrontation (bitemporal hemianopia), pupil reactivity, extraocular movements (CN III/IV/VI palsy) [6]
- Genitourinary: Testicular volume (orchidometer — <5 mL suggests severe hypogonadism), consistency, presence of varicocele, penile length [2][5]
- Breast: Gynecomastia (more common in primary hypogonadism), galactorrhea [2][5]
- Body habitus: Eunuchoidal proportions (arm span > height by >5 cm), central obesity, decreased muscle mass [1][5]
- Hair/skin: Decreased body/facial hair, decreased frequency of shaving, fine wrinkles [5]
- Neurologic: Anosmia testing (Kallmann), synkinesia (mirror movements), mental status [2]
- Prostate: Digital rectal exam (baseline before TRT consideration) [1]
11. Lab Studies
Initial workup
- Total testosterone — fasting, morning (7–10 AM), on ≥2 separate days; <300 ng/dL confirms biochemical hypogonadism [1-2][13]
- Free testosterone — if total testosterone is borderline low or conditions altering SHBG (obesity, liver disease, aging) [2-3]
- LH and FSH — to classify primary (elevated) vs. secondary (low/normal) hypogonadism [1]
- Prolactin — to evaluate for prolactinoma (especially if secondary hypogonadism) [5][7]
- CBC with hematocrit — anemia common in hypogonadism; baseline needed before TRT [2]
- BMP — hyponatremia (SIADH or adrenal insufficiency in pituitary disease) [7]
Additional labs based on clinical suspicion
- Iron studies / ferritin — hemochromatosis screening [1][5]
- Cortisol (AM) / ACTH — if pituitary apoplexy or panhypopituitarism suspected [3][7]
- TSH, free T4 — concurrent central hypothyroidism [3]
- PSA — baseline in men ≥40 before TRT [1][13]
- SHBG — if discrepancy between total testosterone and clinical picture [2]
- Karyotype — if unexplained primary hypogonadism in a young man (Klinefelter 47,XXY) [2][5]
Important caveat: Do NOT diagnose hypogonadism during acute illness — testosterone is transiently suppressed. [2][5]
12. Imaging
- MRI of the sella turcica (gold standard for pituitary pathology): Indicated when secondary hypogonadism is confirmed AND any of the following are present: [2][5]
- Visual field defects or cranial nerve palsies
- Other pituitary hormone deficiencies
- Any degree of hyperprolactinemia
- Very low testosterone (<150 ng/dL)
- Suspected pituitary apoplexy (urgent MRI)
- CT head (non-contrast): Useful in the acute setting if MRI unavailable; can identify acute hemorrhage in pituitary apoplexy [6]
- Scrotal ultrasound: If testicular pathology suspected (mass, torsion, varicocele)
- DEXA scan: For men with fragility fractures, height loss, or known low bone mass — not acute [5]
Routine sellar MRI in middle-aged/older men with secondary hypogonadism without alarm features has low yield and is not universally recommended. [1-2][5]
13. Special Tests
- ADAM Questionnaire (Androgen Deficiency in the Aging Male): Validated screening tool for symptomatic hypogonadism [13]
- Semen analysis: If infertility is a concern [1-2]
- Formal visual field testing (Humphrey or Goldmann): If sellar mass identified or visual symptoms present [6]
- GnRH stimulation test: Generally NOT useful in adults; may be used in pediatric evaluation in some countries [3]
- Genetic testing: For congenital hypogonadotropic hypogonadism (>60 genes identified; mutations found in ~50% of cases) [2]
- Pituitary Apoplexy Score: Helps guide surgical vs. conservative management in confirmed apoplexy [19]
14. ECG
- Not routinely indicated for hypogonadism evaluation
- Obtain ECG if:
- Hemodynamic instability (adrenal crisis — look for hyperkalemia patterns in primary AI)
- Pre-TRT cardiovascular risk assessment in older men
- Suspected QTc prolongation from concurrent medications
- Hypogonadism itself is associated with increased cardiovascular risk, but ECG changes are nonspecific [15]
15. Assessment
Severity stratification
- Mild: Sexual symptoms only, testosterone 200–300 ng/dL — outpatient workup
- Moderate: Multiple symptoms (sexual + constitutional), testosterone <200 ng/dL — expedited outpatient evaluation with endocrinology
- Severe/Emergent: Pituitary apoplexy (headache + visual loss + hemodynamic instability), adrenal crisis, or testicular torsion — requires immediate ED management [3][7]
Key clinical pearls
- Sexual symptoms (low libido, erectile dysfunction, poor morning erections) have the strongest syndromic association with low testosterone and the greatest likelihood of improvement with treatment [1-2]
- ~30% of men with an initially low testosterone will have normal levels on repeat testing — confirmation is essential [20]
- Functional hypogonadism (obesity, opioids, illness) is potentially reversible by addressing the underlying cause [1]
16. Treatment Plan
Acute/Emergent management
- Pituitary apoplexy: IV hydrocortisone 100–200 mg bolus, then 50–100 mg q6h; hemodynamic stabilization; urgent neurosurgery and ophthalmology consultation [7][19]
- Adrenal crisis: IV hydrocortisone 100 mg bolus + aggressive IV fluid resuscitation; correct hyponatremia and hypoglycemia [7][21]
- Testicular torsion: Emergent surgical exploration (within 6 hours)
Non-emergent testosterone replacement therapy (outpatient initiation after confirmed diagnosis):
- Transdermal gel (preferred for initiation in older men): Testosterone gel 1.62% — starting dose 40.5 mg daily to shoulders/upper arms; titrate at 14 and 28 days based on morning testosterone levels [12][14]
- Injectable testosterone cypionate/enanthate: 100–200 mg IM every 1–2 weeks [1]
- Goal: Mid-normal testosterone range (450–600 ng/dL) [1][22]
Monitoring on TRT: [1]
- Testosterone levels, hematocrit, and symptom assessment at 3–6 months, then annually
- PSA and DRE at baseline and 3–12 months after initiation (men ≥40)
- Stop TRT if hematocrit >54% — evaluate for hypoxia/sleep apnea [1]
- BMD after 1–2 years if osteoporosis present [1]
Fertility-preserving alternatives (secondary hypogonadism): Gonadotropin therapy (hCG ± FSH) or clomiphene citrate rather than exogenous testosterone [1][5]
17. Disposition
Admit
- Pituitary apoplexy with visual deterioration, altered consciousness, or hemodynamic instability [7][19]
- Adrenal crisis requiring IV hydrocortisone and fluid resuscitation [7]
- Testicular torsion (surgical admission)
- Severe hyponatremia or hemodynamic compromise from any cause
Observation
Discharge
- Stable patients with suspected hypogonadism and no alarm features — arrange outpatient endocrinology follow-up
- Patients with functional hypogonadism (opioid-induced, obesity-related) — address reversible causes, arrange outpatient labs
Specialist consultation triggers
- Endocrinology: All confirmed hypogonadism, panhypopituitarism, congenital causes
- Neurosurgery: Pituitary apoplexy, sellar mass with mass effect
- Urology: Prostate abnormalities pre-TRT, infertility, testicular pathology
- Hematology: Hematocrit >54% on TRT [13]
18. Follow Up / Return Precautions
Follow-up timing
- If discharged with suspected hypogonadism: Outpatient fasting AM testosterone within 1–2 weeks (must be drawn 7–10 AM, fasting, after adequate sleep, and NOT during acute illness) [2]
- On TRT: Follow-up at 3–6 months, then annually [1][14]
Return precautions — instruct patients to return immediately for:
- Sudden severe headache with visual changes (pituitary apoplexy)
- Dizziness, fainting, or persistent nausea/vomiting (adrenal crisis)
- Acute scrotal pain or swelling
- Chest pain, shortness of breath, leg swelling (thromboembolism — particularly if on TRT) [18]
Patient counseling
- Functional hypogonadism from obesity or opioids may resolve with weight loss or opioid cessation [1][23]
- TRT suppresses spermatogenesis and is NOT a form of contraception — discuss fertility implications [1][24]
- Expected timeline for symptom improvement on TRT: libido may improve within weeks; body composition changes take 3–6 months [22]
The following diagnostic algorithm illustrates the systematic evaluation of male hypogonadism:
References
1. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. — Bhasin S, Brito JP, Cunningham GR, et al. The Journal of Clinical Endocrinology and Metabolism. 2018.
2. Male Hypogonadism: Pathogenesis, Diagnosis, and Management. — De Silva NL, Papanikolaou N, Grossmann M, et al. The Lancet. Diabetes & Endocrinology. 2024.
3. Hypopituitarism. — Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Lancet. 2024.
4. Pituitary Apoplexy: An Updated Review. — Iglesias P. Journal of Clinical Medicine. 2024.
5. Male Hypogonadism. — Basaria S. Lancet. 2014.
6. Hypopituitarism. — Vance ML. The New England Journal of Medicine. 1994.
7. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. — Fleseriu M, Hashim IA, Karavitaki N, et al. The Journal of Clinical Endocrinology and Metabolism. 2016.
8. Pituitary Apoplexy. — Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Endocrine Reviews. 2015.
9. Opioid-Induced Endocrinopathies. — Fountas A, Van Uum S, Karavitaki N. The Lancet. Diabetes & Endocrinology. 2020.
10. Opioids and Their Endocrine Effects: A Systematic Review and Meta-Analysis. — de Vries F, Bruin M, Lobatto DJ, et al. The Journal of Clinical Endocrinology and Metabolism. 2020.
11. Adrenal Insufficiency. — Husebye ES, Pearce SH, Krone NP, Kämpe O. Lancet. 2021.
12. FDA Drug Label. — Updated date: 2024-09-30. Food and Drug Administration.
13. Testosterone Replacement Therapy for Male Hypogonadism. — Heidelbaugh JJ, Belakovskiy A. American Family Physician. 2024.
14. EMAS Position Statement: Testosterone Replacement Therapy in Older Men. — Kanakis GA, Pofi R, Goulis DG, et al. Maturitas. 2023.
15. Testosterone and Cardiovascular Disease. — Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Journal of the American College of Cardiology. 2016.
16. How Would You Manage This Male Patient With Hypogonadism? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. — Libman H, Cohen ML, Irwig MS, Smetana GW. Annals of Internal Medicine. 2021.
17. Anabolic-Androgenic Steroid Use in Sports, Health, and Society. — Bhasin S, Hatfield DL, Hoffman JR, et al. Medicine and Science in Sports and Exercise. 2021.
18. Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism. — Bhasin S, Snyder PJ. The New England Journal of Medicine. 2025.
19. Management of Endocrine Disease: Update on the Management of Pituitary Apoplexy. — Biagetti B, Marques P, Ntali G, et al. European Journal of Endocrinology. 2026.
20. Testicular function. — Sandeep Dhindsa Pathy's Principles and Practice of Geriatric Medicine 6e. 2022.
21. What Is Adrenal Insufficiency?. — Voelker R. The Journal of the American Medical Association. 2026.
22. Testosterone Therapy in Adult Males With Hypogonadism. — Boeri L, Masterson T, Antonio L, et al. European Urology. 2025.
23. Endocrinopathies and Their Recovery in a 20-Year Cohort Study of People With Heroin Dependence. — Tremonti C, Twigg SM, Mills KL, et al. Clinical Endocrinology. 2026.
24. Testosterone Replacement in Men With Sexual Dysfunction. — Lee H, Hwang EC, Oh CK, et al. The Cochrane Database of Systematic Reviews. 2024.